Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
Cancer Prevention and Control Program, Cedars Cancer, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Clin Infect Dis. 2023 Feb 8;76(3):e692-e701. doi: 10.1093/cid/ciac581.
Understanding the natural history of anal high-risk human papillomavirus (hrHPV) infection is key for designing anal cancer prevention programs but has not been systematically characterized.
We reanalyzed data from 34 studies including 16 164 individuals in 6 risk groups defined by human immunodeficiency virus (HIV) status, sex, and male sexuality: men who have sex with men (MSM) and people with HIV (MSMWH), HIV-negative MSM, women with HIV (WWH), HIV-negative women, men who have sex with women (MSW) with HIV (MSWWH), and HIV-negative MSW. We used Markov models to estimate incidence and clearance of 13 hrHPV types and their determinants.
Human papillomavirus (HPV) 16 had the highest incidence-clearance ratio of the hrHPV types. MSMWH had the highest hrHPV incidence (eg, 15.5% newly HPV-16 infected within 2 years), followed by HIV-negative MSM (7.5%), WWH (6.6%), HIV-negative women (2.9%), MSWWH (1.7%), and HIV-negative MSW (0.7%). Determinants of HPV-16 incidence included HIV status and number of sexual partners for MSM, women, and MSW, and anal sex behavior for MSM only. HPV-16 clearance was lower for people with HIV (PWH) and lower for prevalent than incident infection. Among MSM, increasing age was associated with lower clearance of prevalent, but not incident, HPV-16 infection.
This robust and unifying analysis of anal hrHPV natural history is essential to designing and predicting the impact of HPV vaccination and HPV-based screening programs on anal cancer prevention, particularly in MSM and PWH. Importantly, it demonstrates the higher carcinogenic potential of longstanding anal prevalent hrHPV infection than more recent incident infection.
了解肛门高危型人乳头瘤病毒(hrHPV)感染的自然史对于设计肛门癌预防计划至关重要,但尚未得到系统描述。
我们重新分析了来自 34 项研究的数据,这些研究包括 6 个风险组的 16164 名个体,这些风险组由人类免疫缺陷病毒(HIV)状态、性别和男性性行为定义:男男性行为者(MSM)和 HIV 感染者(MSMWH)、HIV 阴性 MSM、HIV 阳性女性(WWH)、HIV 阴性女性、与女性发生性行为的男性(MSW)且 HIV 阳性(MSWWH)、以及 HIV 阴性 MSW。我们使用马尔可夫模型来估计 13 种 hrHPV 类型及其决定因素的发病率和清除率。
HPV16 是所有 hrHPV 类型中发病率-清除率比值最高的类型。MSMWH 的 hrHPV 发病率最高(例如,在 2 年内有 15.5%的新 HPV-16 感染者),其次是 HIV 阴性 MSM(7.5%)、WWH(6.6%)、HIV 阴性女性(2.9%)、MSWWH(1.7%)和 HIV 阴性 MSW(0.7%)。HPV-16 发病率的决定因素包括 MSM、女性和 MSW 的 HIV 状态和性伴侣数量,以及 MSM 仅有的肛交行为。PWH 人群 HPV-16 清除率较低,且现患感染清除率低于新发感染。在 MSM 中,年龄增加与现患 HPV-16 感染清除率降低相关,但与新发感染无关。
对肛门高危型 HPV 自然史的这种稳健而统一的分析,对于设计和预测 HPV 疫苗和 HPV 筛查计划对肛门癌预防的影响至关重要,尤其是在 MSM 和 PWH 中。重要的是,它表明与近期新发感染相比,长期存在的肛门高危型 HPV 现患感染具有更高的致癌潜力。